Safety and efficacy of oxycodone for refractory dyspnea in end-stage heart failure patients with chronic kidney disease: a case series of eight patients

Table 3 Characteristics before and after oxycodone administration

Case	Starting dosage (mg/day)	Maintenance dosage (mg/day)	Elapsed time until MBS improved well	MBS score		sBP (mmHg)		Heart rate (bpm)		Respiratory rate (bpm)		Adverse effect	Period of administration (day)	Reasons for termination
Case	Starting dosage (mg/day)	Maintenance dosage (mg/day)	Elapsed time until MBS improved well	Before	After	Before	After	Before	After	Before	After	Adverse effect	Period of administration (day)	Reasons for termination
1	10	10	2 days	10	2	111	94	86	100	25	16	Constipation, nausea, tremor	12 days	Improved
2	10	10	7 days	10	2	80	100	110	90	15	20	None	29 days	Improved
3	6.6	10	2 days	9	8	98	113	103	108	19	26	None	4 days	Death
4	5	10	2 days	10	7	111	102	80	54	23	16	None	6 days	Death
5	5	5	1 day	8	3	85	80	133	102	18	18	PT-INR prolonged, tremor	10 days	Improved
6	7.5	7.5	1 day	10	2	102	111	95	78	26	20	None	35 days	Death
7	6	6	2 h	7	1	99	107	94	92	22	18	Tremor	8 days	Improved
8	10	10	2 days	7	3	129	115	71	72	23	20	None	23 days	Death

MBS Modified Borg scale, sBP Systolic blood pressure, PT-INR International normalized ratio of prothrombin time, Before Before oxycodone administration, After When MBS scores had improved

ISSN: 2055-0294